NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
ID: 340830Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/340830

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-194.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity for the NHLBI TOPMed program, aimed at generating integrated genetic and multi-omics data to enhance the understanding of heart, lung, blood, and sleep (HLBS) disorders. This X01 Resource Access Award invites applications that utilize NHLBI-funded resources to uncover molecular mechanisms related to these disorders, transitioning from genetic mapping to a comprehensive understanding of disease pathobiology. While no direct funding will be provided, applicants are encouraged to access omics data from NIH-designated controlled-access databases, with a focus on addressing significant knowledge gaps using well-characterized biospecimens. Interested applicants must submit their proposals by October 17, 2024, and can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-194-Full-Announcement.html
    PAR-22-194.html
    The National Institutes of Health (NIH) has released a Funding Opportunity Announcement (FOA) for the NHLBI TOPMed program, aimed at generating genetic and multi-omics data to understand heart, lung, blood, and sleep (HLBS) disorders. This X01 Resource Access Award invites applications that will utilize NHLBI-funded resources to uncover molecular mechanisms related to these disorders, transitioning from a genetic mapping approach to a comprehensive understanding of disease pathobiology. No direct funding will be provided; instead, applicants must access omics data stored in NIH-designated controlled-access databases like dbGaP. The FOA encourages participation in data sharing and integration, with a focus on leveraging existing datasets to address significant knowledge gaps. Applications are required to involve well-characterized biospecimens and demonstrate the relevance of the proposed research to HLBS health. Key eligibility includes various institutions such as higher education and non-profit organizations, emphasizing diversity among applicants. Submission guidelines stress adherence to application instructions, and no clinical trials are allowed under this FOA. The anticipated number of projects awarded is up to 10, covering a maximum project period of three years. Proposals should outline a clear scientific approach, and detailed instructions for application submission are provided, aligning with NIH policies.
    Similar Opportunities
    NHLBI Program Project Applications (P01 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for Program Project (P01) grant applications aimed at advancing research in heart, lung, and blood diseases. Applicants are required to submit proposals that include a minimum of three interrelated research projects focused on a common biomedical theme, with the option to incorporate clinical trials. This initiative is designed to foster collaborative research efforts and encourage innovative scientific directions, particularly supporting projects led by Early Stage Investigators (ESIs). The maximum funding for awarded projects is capped at $1.515 million annually, or $1.765 million if an ESI-led project is included, with a project duration of up to five years. Interested applicants can find more information and submit their proposals electronically via Grants.gov, with a closing date for applications set for September 25, 2026. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research (R21)" to support exploratory research utilizing existing biospecimens relevant to heart, lung, and blood diseases. This grant aims to enhance the scientific utility of the NHLBI Biologic Specimen Repository by encouraging researchers to generate preliminary data that can inform future studies, with a focus on maximizing the value of stored collections. A total of $1,155,000 is anticipated for competitive awards from FY2023 through FY2025, with individual budgets capped at $75,000 for a maximum two-year project period. Interested applicants must submit their proposals by December 10, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity (FON: PAR-24-173) aimed at supporting Phase I clinical trials for therapeutics and diagnostics related to heart, lung, blood, and sleep (HLBS) disorders in both adults and children. This initiative utilizes a bi-phasic R61/R33 award mechanism, where the R61 phase focuses on preparatory activities such as finalizing trial protocols and gathering preclinical data, while the R33 phase is dedicated to executing the clinical trial. The funding limits include up to $250,000 annually for the R61 phase and $1,515,000 for the R33 phase, with total support available for a maximum of five years. Interested applicants must adhere to NIH guidelines and submit their proposals by January 7, 2027, to be considered for this opportunity. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "Omics Phenotypes Related to Down Syndrome for the INCLUDE Project (X01 Clinical Trial Not Allowed)." This initiative invites applications to utilize existing biospecimens to generate integrated genomic and multi-omics data aimed at uncovering the molecular mechanisms associated with health conditions related to Down syndrome. The program emphasizes the importance of including cohorts from underrepresented racial and ethnic groups and does not provide direct funding; instead, it facilitates access to sequencing resources for various genomic profiling techniques. Interested applicants should note that the earliest submission date is February 13, 2024, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-081.html.
    Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), has announced a funding opportunity for exploratory R21 grant applications focused on secondary analyses of existing human datasets related to heart, lung, blood diseases, and sleep disorders. The objective of this grant is to stimulate innovative research by utilizing existing datasets to explore novel scientific ideas and develop impactful biomedical tools and technologies, without the need for new primary data collection. This initiative is crucial for advancing public health research aligned with NHLBI priorities, with an annual funding commitment of up to $2,187,000 over three years, supporting approximately eighteen new awards each year, with a maximum of $75,000 in direct costs per application for a two-year project period. Interested applicants can find more information and application guidelines at NIH Grants, and should note that the application deadline is January 7, 2026.
    NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NHLBI Outstanding Investigator Award (OIA), a federal grant aimed at supporting experienced Program Directors/Principal Investigators (PDs/PIs) engaged in heart, lung, blood, and sleep (HLBS) research. This award provides long-term funding of up to $700,000 annually for a maximum of seven years, allowing recipients to pursue innovative research initiatives without the constraints of predefined aims, thereby enhancing scientific productivity and flexibility. The OIA is designed to foster a stable research environment, reduce administrative burdens, and facilitate mentoring of junior scientists, with applications due by April 28, 2027. For further details, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-002.html.
    Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)" aimed at enhancing the use and sharing of genomic information in clinical care across diverse populations. This initiative seeks proposals that focus on understanding the implementation of genomic medicine, addressing barriers to access, and developing analytical tools for clinical genomic data, with a strong emphasis on inclusivity for populations experiencing health disparities. The NIH has allocated approximately $2.4 million for three projects, with an additional project funded by the National Cancer Institute, and applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their proposals. Interested parties must submit their applications by February 11, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research" grant, aimed at advancing technologies that address heart, lung, blood, and sleep (HLBS) disorders. This funding opportunity specifically seeks R33 exploratory/developmental grant applications that focus on mid-stage developments requiring further validation and refinement, with an emphasis on demonstrating novelty and substantial improvement over existing methods. The initiative is crucial for facilitating transformations in HLBS-related research and clinical practices, promoting the swift adoption of breakthrough technologies. Interested applicants can apply for funding of up to $1.86 million annually, with a submission deadline of December 20, 2024. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01), which invites researchers to apply for access to valuable biospecimens collected from an ongoing longitudinal study focused on tobacco use behaviors and health outcomes in the U.S. This initiative primarily provides urine, plasma, serum, and genomic DNA samples to support research relevant to tobacco regulations under the Family Smoking Prevention and Tobacco Control Act. The PATH Study, launched in 2011, plays a crucial role in advancing scientific understanding of tobacco use and its implications for public health. Applications will open on March 30, 2024, and close on October 31, 2026, with evaluations based on alignment with PATH objectives and the merit of proposed research. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.